Foreword: Yehuda Shoenfeld and M. Eric Gershwin.
.
Part I: Organ-Specific Autoimmune Diseases:.
1. Activation, Apoptosis, and Clearance of Neutrophils in
Wegener's Granulomatosis: Andre P. van Rossum, Pieter C.
Limburg, and Cees G. M. Kallenberg.
2. Is PR3-ANCA Formation Initiated in Wegener's Granulomatosis
Lesions? Granulomas as Potential Lymphoid Tissue Maintaining
Autoantibody Production: J Voswinkel, A Muller, and P
Lamprecht.
3. Clinical Relevance of Antiphospholipid Antibodies in Primary
Biliary Cirrhosis: Philipp von Landenberg, Michael Baumgartner,
Juergen Schoelmerich, Karl J. Lackner, and Reinhild Klein.
4. IL-10 and the Cytokine Network in the Pathogenesis of Human
Autoimmune Hemolytic Anemia: Caterina Toriani-Terenzi and Enzo
Fagiolo.
5. Crohn's Disease Is Associated with Polymorphism of
CARD15/NOD2 Gene in a Hungarian Population: Zsuzsanna Nagy,
Oszkar Karadi, Gyorgy Rumi, Gyorgy Rumi, Jr.,
Alajos Par, Gyula Mozsik, Laszlo Czirjak,
and Gabor Suto.
6. Apoptosis in Human Skin: Role in Pathogenesis of Various
Diseases and Relevance for Therapy: Esther Reefman, Pieter C.
Limburg, Cees G. M. Kallenberg, and Marc Bijl.
7. Cancer-Associated Myositis: Clinical Features and Prognostic
Signs: Andrea Ponyi, Tamas Constantin, Miklos Garami,
Csilla andras, Bela Tallai, Andrea Vancsa,
Lajos Gergely, and Katalin Danko.
8. Control of Type 1 Autoimmune Diabetes by Naturally Occurring
CD4+CD25+ Regulatory T Lymphocytes in Neonatal NOD Mice: C A
Piccirillo, M Tritt, E Sgouroudis, A Albanese, M Pyzik, and V
Hay.
9. The Role of Methallothioneins in Experimental Autoimmune
Encephalomyelitis and Multiple Sclerosis: Carmen Espejo and Eva M.
Martinez-Caceres.
10. Oxidized Low-Density Lipoprotein/ß2-Glycoprotein I
Complexes and Autoantibodies in Patients with Type 2 Diabetes
Mellitus: Luis R. Lopez, Beth L. Hurley, Daniel F. Simpson, and
Eiji Matsuura.
11. Autoantibodies to Human 6 Integrin in Patients with Bullous
Pemphigoid: Maria Kiss, Adam Perenyi, Ilona
Marczinovits, Janos Molnar, Attila Dobozy, Lajos
Kemeny, and Sandor Husz.
12. Soluble HLA Class I and Class II Molecules in
Relapsing-Remitting Multiple Sclerosis: Acute Response to
Interferon-ß1a Treatment and Their Use as Markers of Disease
Activity: Alireza Minagar, Irena Adamashvilli, Stephen L. Jaffe,
Michael F. Glabus, Eduardo Gonzalez-Toledo, and Roger E.
Kelley.
13. Proinflammatory Cytokines and Autoimmunity in Churg-Strauss
Syndrome: B Hellmich, E Csernok, and W L Gross.
14. Rheumatic Fever: How S. pyogenes-Primed Peripheral T Cells
Trigger Heart Valve Lesions: L Guilherme, K C Fae, S E Oshiro,
A C Tanaka, P M A Pomerantzeff, and J Kalil.
15. Avidity of Anti-ß2-Glycoprotein I and Thrombosis or
Pregnancy Loss in Patients with Antiphospholipid Syndrome: S
Cucnik, B Bozic, T Kveder, M Tomsic, and B Rozman.
16. Neurological Complications of Celiac Disease and Autoimmune
Mechanisms: Preliminary Data of a Prospective Study in Adult
Patients: C Briani, G Zara, E Toffanin, S Ruggero, A Ferrarini, F
De Lazzari, M Luca, D Faggian, F Grassivaro, M Ermani, R Pezzani, B
Giometto, and A D'odorico.
17. E2F1?/? C57BL/6 Mice Overexpressing a Human
Bcl-2 Transgene in B Cells Develop a Mild Autoimmune Syndrome:
Maria J. Marin, Itxaso Garcia, Marta Pena,
Ainhoa Bolivar, Ana Zubiaga, and Marcos Loez-Hoyos.
18. Systemic Thromboembolism in Inflammatory Bowel Disease:
Mechanisms and Clinical Applications: Gilad Twig, Gisele
Zandman-Goddard, Martine Szyper-Kravitz, and Yehuda Shoenfeld.
19. Pregnancy Loss and Endometriosis: Pathogenic Role of
Anti-Laminin-1 Autoantibodies: Junko Inagaki, Akane Kondo, Luis R.
Lopez, Yehuda Shoenfeld, and Eiji Matsuura.
20. Primary Biliary Cirrhosis: Solving the Enigma: Alessia
Giorgini, Carlo Selmi, Pietro Invernizzi, Mauro Podda, Massimo
Zuin, and M Eric Gershwin.
21. The Stages of Type 1A Diabetes: Naru Babaya, Maki Nakayama,
and George S. Eisenbarth.
22. Soluble CD40L in Plasma of Patients with Primary Biliary
Cirrhosis: Sabine Oertelt, Pietro Invernizzi, Carlo Selmi, Mauro
Podda, and M Eric Gershwin.
23. Decreased Serum Leptin Levels in Primary Biliary Cirrhosis:
A Link between Metabolism and Autoimmunity?: Roman Rieger, Sabine
Oertelt, Carlo Selmi, Pietro Invernizzi, Mauro Podda, and M Eric
Gershwin.
24. Analysis of the Foxp3/Scurfin Gene in Crohn's Disease: Ogyi
Park, Irina Grishina, Patrick S. Leung, M Eric Gershwin, and T
Prindiville.
.
Part II: Systematic Autoimmune Diseases:.
25. Juvenile Systemic Sclerosis: A Follow-up Study of Eight
Patients: Szilvia Szamosi, Laszlo Marodi,
Laszlo Czirjak, Zoltan Ellenes, and Gabriella
Szucs.
26. Antifodrin Antibodies in Sjogren's Syndrome: A Review:
Torsten Witte.
27. Generation and Characterization of Three Monoclonal IgM
Antiphospholipid Antibodies Recognizing Different Phospholipid
Antigens: Catharina Buschmann, Christian Fischer, Viola Ochsenhirt,
Carolin Neukirch, Karl J. Lackner, and Philipp von Landenberg.
28. Premature Immunosenescence in Rheumatoid Arthritis and
Multiple Sclerosis Patients: Marielle Thewissen, Loes Linsen,
Veerle Somers, Piet Geusens, Jef Raus, and Piet Stinissen.
29. Association of Rheumatoid Arthritis with HLA-DR1 and HLA-DR4
in Hungary: Aniko Kapitany, Erika Zilahi, Sandor
Szanto, Gabriella Szucs, Zoltan Szabo,
Aniko Vegvari, Peter Rass, Sandor Sipka,
Gyula Szegedi, and Zoltan Szekanecz.
30. Plasminogen Activator Inhibitor-1 Is Associated with
Impaired Endothelial Function in Women with Systemic Lupus
Erythematosus: Emily C. Somers, Wendy Marder, Mariana J. Kaplan,
Robert D. Brook, and W Joseph McCune.
31. Early Atherosclerosis in Rheumatoid Arthritis: Effects of
Smoking on Thickness of the Carotid Artery Intima Media: Roberto
Gerli, Yaniv Sherer, Gaetano Vaudo, Giuseppe Schillaci, Boris
Gilburd, andrea Giordano, Elena Bartoloni Bocci, Rosita Allegrucci,
Simona Marchesi, Elmo Mannarino, and Yehuda Shoenfeld.
32. Investigation of Arthritic Joint Destruction by a Novel
Fibroblast-Based Model: U Sack, B Sehm, F Kahlenberg, A Murr, J
Lehmann, A Tannapfel, K Uberla, A Moessner, A Dietrich, F Emmrich,
F Lange, A Jungel, J-M Braun, and U Anderegg.
33. Prevalence of Antiphospholipid and Antioxidized Low-Density
Lipoprotein Antibodies in Rheumatoid Arthritis: Yaniv Sherer,
Roberto Gerli, Gaetano Vaudo, Giuseppe Schillaci, Boris Gilburd,
andrea Giordano, Elena Bartoloni Bocci, Rosita Allegrucci, Simona
Marchesi, Elmo Mannarino, and Yehuda Shoenfeld.
34. Mono-organic versus Multi-organic Involvement in Primary
Antiphospholipid Syndrome: Gabriela Medina, Olga Vera-Lastra,
Ulises Angeles, and Luis J. Jara.
35. OxLDL/ß2GPI Complexes and Autoantibodies in Patients
with Systemic Lupus Erythematosus, Systemic Sclerosis, and
Antiphospholipid Syndrome: Pathogenic Implications for Vascular
Involvement: Luis R. Lopez, Daniel F. Simpson, Beth L. Hurley, and
Eiji Matsuura.
36. Anti-HSP60 Immunity Is Already Associated with
Atherosclerosis Early in Life: M Knoflach, D Bernhard, and G
Wick.
37. Determinants of Vessel Targeting in Vasculitis: Gary S.
Hoffman.
38. Lymphocyte Activation as a Possible Measure of
Atherosclerotic Risk in Patients with Sleep Apnea: Larissa
Dyugovskaya, Peretz Lavie, and Lena Lavie.
39. Systemic Lupus Erythematosus, Atherosclerosis, and
Autoantibodies: Sandra Zampieri, Luca Iaccarino, Anna Ghirardello,
Elena Tarricone, Silvia Arienti, Piercarlo Sarzi-Puttini,
Pierfranca Gambari, and andrea Doria.
40. Accelerated Atherosclerosis in Patients with Systemic
Autoimmune Diseases: Karina de Leeuw, Cees Kallenberg, and Marc
Bijl.
41. Nocturnal Hormones and Clinical Rhythms in Rheumatoid
Arthritis: Maurizio Cutolo, Kati Otsa, Oivi Aakre, and Alberto
Sulli.
42. Xenobiotic-Induced Recruitment of Autoantigens to Nuclear
Proteasomes Suggests a Role for Altered Antigen Processing in
Scleroderma: Min Chen and Anna von Mikecz.
43. Humoral Antigenic Targets of the Ribosomal P0 Lupus
Autoantigen Are Not Limited to the Carboxyl Region: Benjamin F.
Bruner, Donny M. Wynn, Morris Reichlin, John B. Harley, and Judith
A. James.
44. Clinical Correlations of Potential Activity Markers in
Systemic Sclerosis: R Becvar, J Stork, V Pesakova, A
Stanova, H Hulejova, L Rysova, A
Zatloukalova, P Zatloukal, M Jachymova, and L
Pourova.
45. Complement Activation: A Novel Pathogenic Mechanism in the
Antiphospholipid Syndrome: Silvia S. Pierangeli, Mariano
Vega-Ostertag, Xiaowei Liu, and Guillermina Girardi.
46. The Interplay of Chemokines and Dendritic Cells in the
Pathogenesis of Lupus Nephritis: Marco Tucci, Nicola Calvani, Hanno
B. Richards, Cosima Quatraro, and Franco Silvestris.
47. Cellular and Molecular Mechanisms of Regulation of
Autoantibody Production in Lupus: Bevra H. Hahn, Fanny Ebling, Ram
R. Singh, Ram P. Singh, George Karpouzas, and Antonio La Cava.
48. The Role of Innate and Adaptive Immunity to Oxidized
Low-Density Lipoprotein in the Development of Atherosclerosis:
Kazuko Kobayashi, Luis R. Lopez, Yehuda Shoenfeld, and Eiji
Matsuura.
49. Predictive Markers for Development of Severe Organ
Involvement in Patients with Systemic Sclerosis: Laure Ysebrant De
Lendonck, Annick Ocmant, Florence Roufosse, and Elie Cogan.
50. Hughes Syndrome, the Antiphospholipid Syndrome: A New
Chapter in Neurology: Giovanni Sanna, Maria Laura Bertolaccini, and
Graham R. V. Hughes.
51. New Facet of Antiphospholipid Antibodies: Guido Valesini and
Cristiano Alessandri.
.
Part III: Treatment:.
52. Inhibitor Development in Patients with Hemophilia A after
Continuous Infusion of FVIII Concentrates: CH von Auer, J
Oldenburg, M von Depka, C Escuriola-Ettinghausen, K Kurnik, H Lenk,
and I Scharrer.
53. Increased Spontaneous Apoptosis of CD4+CD25+ T Cells in
Patients with Active Rheumatoid Arthritis Is Reduced by Infliximab:
E Toubi, A Kessel, Z Mahmudov, K Hallas, M Rozenbaum, and I
Rosner.
54. Synergistic Effect of Avemar on Proinflammatory Cytokine
Production and Ras-Mediated Cell Activation: Andras Telekes,
Endre Kiss-Toth, Tunde Nagy, Eva E. Qwarnstrom,
Erzsebet Kusz, Timea Polgar, Akos Resetar,
Steven K. Dower, and Erno Duda.
55. Fermented Wheat Germ Extract (Avemar) in the Treatment of
Cancer and Autoimmune Diseases: Laszlo G. Boros, Michele
Nichelatti, and Yehuda Shoenfeld.
56. Open-Label 24-Month Study Evaluating Infliximab Therapy in
Patients with Psoriatic Spondyloarthropathy: J J Scali, A Kaminsky,
J Salomon, S Visentini, and E Dancziger.
57. Cyclosporine: From Renal Transplantation to Autoimmune
Diseases: Claudio Ponticelli.
58. Autoimmunity and Anti-TNF- Agents: Fabiola Atzeni, Maurizio
Turiel, Franco Capsoni, andrea Doria, Pierluigi Meroni, and
Piercarlo Sarzi-Puttini.
59. Combination Treatment of Rat Adjuvant-Induced Arthritis with
Methotrexate, Probiotic Bacteria Enterococcus faecium, and
Selenium: Jozef Rovensky, Karol Svik, Vladimir Matha,
Richard Istok, Vojtech Kamarad, Libor Ebringer, Miroslav
Ferencik, and Maria Stancikova.
60. Comparative Analysis of Antigen Specificities in the
Monomeric and Dimeric Fractions of Intravenous Immunoglobulin:
Sylvia M. Miescher, Alexander Schaub, Marco Ghielmetti, Michael
Baumann, Monique Vogel, Reinhard Bolli, and Beda Stadler.
61. Treatment of Pemphigus Vulgaris with Protein A
Immunoadsorption: Case Report of Long-Term History Showing
Favorable Outcome: Nina Frost, Gerald Messer, Gerhard Fierlbeck,
Teut Risler, and Simon D. Lytton.
62. Immunosuppressive Therapy and Clinical Evolution in
Forty-nine Patients with Antineutrophil Cytoplasmic
Antibody-Associated Glomerulonephritis: E Kokolina, E Alexopoulos,
C Dimitriadis, A Vainas, P Giamalis, A Papagianni, D Ekonomidou,
and D Memmos.
63. Management of Thrombosis in Antiphospholipid Syndrome and
Systemic Lupus Erythematosus in Pregnancy: Guillermo Ruiz-Irastorza
and Munther A. Khamashta.
64. Gene-Gun Biolistic Immunization Encoding Glutamic Acid
Decarboxylase: A Model for Studying Langerhans Cell Abnormalities
and Mimicry in the Nonobese Diabetic Mouse: Beatrice
Joussemet, Anh-Tuan Vu, Pierre Sai, and Jean-Marie Bach.
65. Intra-bone Marrow-Bone Marrow Transplantation: A New
Strategy for Treatment of Stem Cell Disorders: Susumu Ikehara.
66. Removal of Pathogenic Autoantibodies by Immunoadsorption:
Alon Y. Hershko and Yaakov Naparstek.
67. Chemokine Receptors: Attractive Targets for Drug Discovery:
Nuria Godessart.
68. Rationale for T Cell Inhibition by Cyclosporin A in Major
Autoimmune Diseases: G F Ferraccioli, P Tomietto, and M De
Santis.
69. Partial Response to Anti-CD20 Monoclonal Antibody Treatment
of Severe Immune Thrombocytopenic Purpura in a Patient with Common
Variable Immunodeficiency: J Carbone, A Escudero, M Mayayo, M
Ballesteros, A Perez-Corral, S Sanchez-Ramon, E Sarmiento, D
Micheloud, and E Fernandez-Cruz.
70. CD20 Mimicry by a mAb Rituximab-Specific Linear Peptide: A
Potential Tool for Active Immunotherapy of Autoimmune Diseases:
Federico Perosa, Elvira Favoino, Maria Antonietta Caragnano, and
Franco Dammacco.
71. Anticytokine Therapy, Especially Anti-Interferon-, as a
Pathogenetic Treatment in TH-1 Autoimmune Diseases: Simon
Skurkovich and Boris Skurkovich.
72. Therapeutic T Cell-Based Vaccination for Neurodegenerative
Disorders: The Role of CD4+CD25+ Regulatory T Cells: Michal
Schwartz and Jonathan Kipnis.
73. Tumor Necrosis Factor Inhibitor Therapy for Rheumatoid
Arthritis: Stanley M. Naguwa.
74. Pathogenesis of Rheumatoid Arthritis: Targeting Cytokines:
Jochen Zwerina, Kurt Redlich, Georg Schett, and Josef S.
Smolen.
75. Anti-inflammatory and Immune Regulatory Properties of
5-androsten-3ß, 17ß-Diol (HE2100), and Synthetic Analogue
HE3204: Implications for Treatment of Autoimmune Diseases: D Auci,
F Nicoletti, K Mangano, R Pieters, S Nierkens, L Morgan, H Offner,
J Frincke, and C Reading.
76. Immunomodulatory Effects of Intravenous Immunoglobulins as a
Treatment for Autoimmune Diseases, Cancer, and Recurrent Pregnancy
Loss: Tal Sapir, Miri Blank, and Yehuda Shoenfeld.
77. Response of Vasculitic Peripheral Neuropathy to Intravenous
Immunoglobulin: Yair Levy, Yosef Uziel, Giesele Zandman, Pnina
Rotman, Hawared Amital, Yaniv Sherer, Pnina Langevitz, Boleck
Goldman, and Yehuda Shoenfeld.
78. Involvement of Innate Immunity in the Development of
Inflammatory and Autoimmune Diseases: Helena
Tlaskalova-Hogenova, Ludmila Tuckova, Renata
Stepankova, Tomas Hudcovic, Lenka
Palova-Jelinkova, Hana Kozakova, Pavel
Rossmann, Daniel Sanchez, Jana Cinova, Tomas Hrncir,
Miloslav Kverka, Lenka Frolova, Holm Uhlig, Fiona Powrie, and
Paul Bland.
79. Do We Need New Treatment That Goes beyond Tumor Necrosis
Factor Blockers for Rheumatoid Arthritis?: Reinhard E. Voll and
Joachim R. Kalden
